A key health ministry panel on June 1 agreed to grant orphan designation to Pfizer’s fidanacogene elaparvovec, a gene therapy for hemophilia B. The Pharmaceutical Affairs and Food Sanitation Council’s (PAFSC) Committee on Regenerative Medicine Products, Biological Products and Biotechnologies…
To read the full story
Related Article
- Pfizer Files Hemophilia B Gene Therapy in Japan
July 1, 2024
REGULATORY
- MHLW to Set Up Expert Panel on Using Disease Registries in Drug Development
January 13, 2026
- Chuikyo Moves to Allow Special Mixed-Billing for Santen’s Myopia Drug
January 13, 2026
- Japan Panel to Review AbbVie’s Aquipta, Ipsen’s Sohonos on January 23
January 13, 2026
- MHLW Pharma Director Says Uniform Drug Price Hike “Not Realistic,” Targeted Support Preferred
January 9, 2026
- MHLW Issues Guidance on Revised PMD Act Ahead of May Enforcement
January 6, 2026
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…





